Exelixis (EXEL) Stock Forecast, Price Target & Predictions
EXEL Stock Forecast
Exelixis stock forecast is as follows: an average price target of $28.97 (represents a -0.31% downside from EXEL’s last price of $29.06) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
EXEL Price Target
The average price target for Exelixis (EXEL) is $28.97 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $18.00. This represents a potential -0.31% downside from EXEL's last price of $29.06.
EXEL Analyst Ratings
According to 16 Wall Street analysts, Exelixis's rating consensus is 'Buy'. The analyst rating breakdown for EXEL stock is 0 'Strong Buy' (0.00%), 13 'Buy' (81.25%), 2 'Hold' (12.50%), 1 'Sell' (6.25%), and 0 'Strong Sell' (0.00%).
Exelixis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 16, 2024 | Christopher Liu | Leerink Partners | $28.50 | $28.50 | - | -1.93% |
| Oct 16, 2024 | Kennen MacKay | RBC Capital | $34.00 | $28.50 | 19.30% | 17.00% |
| Oct 16, 2024 | Chris Shibutani | Goldman Sachs | $18.00 | $28.50 | -36.84% | -38.06% |
| Oct 15, 2024 | Akash Tewari | Jefferies | $33.00 | $28.80 | 14.60% | 13.56% |
| Oct 15, 2024 | Jeffrey Hung | Morgan Stanley | $30.00 | $28.50 | 5.26% | 3.23% |
| Oct 14, 2024 | Asthika Goonewardene | Truist Financial | $33.00 | $26.24 | 25.76% | 13.56% |
| Oct 14, 2024 | Sudan Loganathan | Stephens | $23.00 | $26.23 | -12.33% | -20.85% |
| Oct 11, 2024 | Jeffrey Hung | Morgan Stanley | $28.00 | $25.97 | 7.82% | -3.65% |
| Sep 19, 2024 | Ashwani Verma | UBS | $30.00 | $26.82 | 11.86% | 3.23% |
| Sep 16, 2024 | David Lebowitz | Citigroup | $31.00 | $26.46 | 17.16% | 6.68% |
The latest Exelixis stock forecast, released on Oct 16, 2024 by Christopher Liu from Leerink Partners, set a price target of $28.50, which represents a 0.00% decrease from the stock price at the time of the forecast ($28.50), and a -1.93% decrease from EXEL last price ($29.06).
Exelixis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 9 | 13 | 16 |
| Avg Price Target | $28.61 | $28.96 | $28.84 |
| Last Closing Price | $29.06 | $29.06 | $29.06 |
| Upside/Downside | -1.55% | -0.34% | -0.76% |
In the current month, the average price target of Exelixis stock is $28.61, according to 9 Wall Street analysts offering twelve months forecast. The average price target represents a -1.55% decrease as opposed to Exelixis's last price of $29.06. This month's average price target is down -1.21% compared to last quarter, and down -0.80% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Oct 16, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 16, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Oct 15, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 15, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 15, 2024 | Morgan Stanley | Positive | Positive | Hold |
| Oct 14, 2024 | Stephens | Equal-Weight | Equal-Weight | Hold |
| Oct 14, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 11, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Exelixis's last stock rating was published by Leerink Partners on Oct 16, 2024. The company gave EXEL a "Market Perform" rating, the same as its previous rate.
Exelixis Financial Forecast
Exelixis Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $479.65M | $471.92M | $469.85M | $408.79M | $423.92M | $411.74M | $419.43M | $355.98M | $451.14M | $328.42M | $385.18M | $270.23M | $270.05M | $231.09M |
| Avg Forecast | $711.40M | $684.30M | $647.50M | $573.60M | $562.70M | $541.60M | $521.20M | $478.30M | $535.52M | $521.20M | $503.22M | $474.32M | $499.75M | $489.15M | $465.47M | $461.04M | $480.33M | $473.48M | $446.29M | $422.66M | $417.61M | $403.47M | $391.03M | $374.45M | $355.78M | $358.58M | $300.03M | $266.56M | $270.00M | $214.67M |
| High Forecast | $711.40M | $684.30M | $647.50M | $573.60M | $562.70M | $541.60M | $521.20M | $478.30M | $535.52M | $521.20M | $503.22M | $474.32M | $499.75M | $497.84M | $465.47M | $461.04M | $514.18M | $497.32M | $446.29M | $422.66M | $417.61M | $403.47M | $391.03M | $374.45M | $355.78M | $358.58M | $300.03M | $266.56M | $270.00M | $214.67M |
| Low Forecast | $711.40M | $684.30M | $647.50M | $573.60M | $562.70M | $541.60M | $521.20M | $478.30M | $535.52M | $521.20M | $503.22M | $474.32M | $499.75M | $480.74M | $465.47M | $461.04M | $449.25M | $446.19M | $446.29M | $422.66M | $417.61M | $403.47M | $391.03M | $374.45M | $355.78M | $358.58M | $300.03M | $266.56M | $270.00M | $214.67M |
| # Analysts | 11 | 7 | 13 | 7 | 7 | 7 | 9 | 7 | 6 | 10 | 6 | 12 | 13 | 14 | 7 | 7 | 10 | 15 | 7 | 7 | 11 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.00% | 1.05% | 0.97% | 1.02% | 1.02% | 1.07% | 0.95% | 1.27% | 0.92% | 1.28% | 1.01% | 1.00% | 1.08% |
Exelixis's average Quarter revenue forecast for Mar 24 based on 7 analysts is $461.04M, with a low forecast of $461.04M, and a high forecast of $461.04M. EXEL's average Quarter revenue forecast represents a -3.88% decrease compared to the company's last Quarter revenue of $479.65M (Dec 23).
Exelixis EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 11 | 7 | 13 | 7 | 7 | 7 | 9 | 7 | 6 | 10 | 6 | 12 | 13 | 14 | 7 | 7 | 10 | 15 | 7 | 7 | 11 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $88.31M | $-17.58M | $77.85M | $28.83M | $-48.08M | $88.28M | $88.48M | $83.24M | $119.95M | $58.06M | $128.56M | $1.21M | $30.54M | $-35.67M |
| Avg Forecast | $131.68M | $126.66M | $119.85M | $106.17M | $104.15M | $100.25M | $96.47M | $88.53M | $99.12M | $96.47M | $93.14M | $87.80M | $92.50M | $90.54M | $86.16M | $70.06M | $88.91M | $87.64M | $82.61M | $63.69M | $77.30M | $74.68M | $72.38M | $50.35M | $65.85M | $66.37M | $55.53M | $1.82M | $49.98M | $39.73M |
| High Forecast | $131.68M | $126.66M | $119.85M | $106.17M | $104.15M | $100.25M | $96.47M | $88.53M | $99.12M | $96.47M | $93.14M | $87.80M | $92.50M | $92.15M | $86.16M | $84.07M | $95.17M | $92.05M | $82.61M | $76.43M | $77.30M | $74.68M | $72.38M | $60.42M | $65.85M | $66.37M | $55.53M | $2.18M | $49.98M | $39.73M |
| Low Forecast | $131.68M | $126.66M | $119.85M | $106.17M | $104.15M | $100.25M | $96.47M | $88.53M | $99.12M | $96.47M | $93.14M | $87.80M | $92.50M | $88.98M | $86.16M | $56.05M | $83.15M | $82.59M | $82.61M | $50.95M | $77.30M | $74.68M | $72.38M | $40.28M | $65.85M | $66.37M | $55.53M | $1.45M | $49.98M | $39.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | -0.20% | 0.94% | 0.45% | -0.62% | 1.18% | 1.22% | 1.65% | 1.82% | 0.87% | 2.31% | 0.67% | 0.61% | -0.90% |
7 analysts predict EXEL's average Quarter EBITDA for Mar 24 to be $70.06M, with a high of $84.07M and a low of $56.05M. This is -20.67% lower than Exelixis's previous annual EBITDA (Dec 23) of $88.31M.
Exelixis Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 11 | 7 | 13 | 7 | 7 | 7 | 9 | 7 | 6 | 10 | 6 | 12 | 13 | 14 | 7 | 7 | 10 | 15 | 7 | 7 | 11 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $85.52M | $1.04M | $81.18M | $40.03M | $-30.17M | $73.21M | $70.67M | $68.57M | $95.17M | $38.20M | $96.09M | $1.60M | $28.39M | $-32.04M |
| Avg Forecast | - | - | - | - | $199.93M | $187.23M | $174.62M | $150.01M | $112.78M | $113.86M | $102.31M | $90.14M | $93.72M | $100.13M | $91.08M | $52.48M | $67.02M | $28.79M | $45.27M | $47.71M | $-32.46M | $56.31M | $57.82M | $37.72M | $17.93M | $57.46M | $17.88M | $2.40M | $16.84M | $2.94M |
| High Forecast | - | - | - | - | $199.93M | $187.23M | $174.62M | $150.01M | $112.78M | $113.86M | $102.31M | $90.14M | $93.72M | $114.44M | $91.11M | $62.98M | $77.83M | $51.82M | $45.27M | $57.25M | $-32.46M | $56.31M | $57.82M | $45.26M | $17.93M | $57.46M | $17.88M | $2.88M | $16.84M | $2.94M |
| Low Forecast | - | - | - | - | $199.93M | $187.23M | $174.62M | $150.01M | $112.78M | $113.86M | $102.31M | $90.14M | $93.72M | $88.21M | $91.06M | $41.98M | $54.05M | $-24.95M | $45.27M | $38.17M | $-32.46M | $56.31M | $57.82M | $30.17M | $17.93M | $57.46M | $17.88M | $1.92M | $16.84M | $2.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.28% | 0.04% | 1.79% | 0.84% | 0.93% | 1.30% | 1.22% | 1.82% | 5.31% | 0.66% | 5.37% | 0.67% | 1.69% | -10.90% |
Exelixis's average Quarter net income forecast for Mar 24 is $52.48M, with a range of $41.98M to $62.98M. EXEL's average Quarter net income forecast represents a -38.63% decrease compared to the company's last Quarter net income of $85.52M (Dec 23).
Exelixis SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 11 | 7 | 13 | 7 | 7 | 7 | 9 | 7 | 6 | 10 | 6 | 12 | 13 | 14 | 7 | 7 | 10 | 15 | 7 | 7 | 11 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $131.44M | $138.14M | $141.72M | $131.40M | $119.25M | $114.98M | $122.76M | $102.86M | $99.31M | $101.56M | $98.50M | $102.35M | $82.44M | $88.19M |
| Avg Forecast | $198.45M | $190.89M | $180.63M | $160.01M | $156.97M | $151.09M | $145.40M | $133.43M | $149.39M | $145.39M | $140.38M | $132.32M | $139.41M | $136.46M | $129.85M | $78.72M | $133.99M | $132.08M | $124.50M | $71.57M | $116.50M | $112.55M | $109.08M | $56.57M | $99.25M | $100.03M | $83.70M | $153.53M | $75.32M | $59.88M |
| High Forecast | $198.45M | $190.89M | $180.63M | $160.01M | $156.97M | $151.09M | $145.40M | $133.43M | $149.39M | $145.39M | $140.38M | $132.32M | $139.41M | $138.88M | $129.85M | $94.47M | $143.44M | $138.73M | $124.50M | $85.88M | $116.50M | $112.55M | $109.08M | $67.89M | $99.25M | $100.03M | $83.70M | $184.23M | $75.32M | $59.88M |
| Low Forecast | $198.45M | $190.89M | $180.63M | $160.01M | $156.97M | $151.09M | $145.40M | $133.43M | $149.39M | $145.39M | $140.38M | $132.32M | $139.41M | $134.11M | $129.85M | $62.98M | $125.32M | $124.47M | $124.50M | $57.25M | $116.50M | $112.55M | $109.08M | $45.26M | $99.25M | $100.03M | $83.70M | $122.82M | $75.32M | $59.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.05% | 1.14% | 1.84% | 1.02% | 1.02% | 1.13% | 1.82% | 1.00% | 1.02% | 1.18% | 0.67% | 1.09% | 1.47% |
Exelixis's average Quarter SG&A projection for Mar 24 is $78.72M, based on 7 Wall Street analysts, with a range of $62.98M to $94.47M. The forecast indicates a -40.11% fall compared to EXEL last annual SG&A of $131.44M (Dec 23).
Exelixis EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 11 | 7 | 13 | 7 | 7 | 7 | 9 | 7 | 6 | 10 | 6 | 12 | 13 | 14 | 7 | 7 | 10 | 15 | 7 | 7 | 11 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.25 | $0.12 | $-0.09 | $0.23 | $0.22 | $0.21 | $0.30 | $0.12 | $0.31 | $0.01 | $0.09 | $-0.10 |
| Avg Forecast | - | - | - | - | $0.68 | $0.64 | $0.59 | $0.51 | $0.38 | $0.39 | $0.35 | $0.31 | $0.32 | $0.34 | $0.31 | $0.22 | $0.23 | $0.10 | $0.15 | $0.16 | $-0.11 | $0.19 | $0.20 | $0.14 | $0.06 | $0.20 | $0.06 | $0.03 | $0.06 | $0.01 |
| High Forecast | - | - | - | - | $0.68 | $0.64 | $0.59 | $0.51 | $0.38 | $0.39 | $0.35 | $0.31 | $0.32 | $0.39 | $0.31 | $0.23 | $0.26 | $0.18 | $0.15 | $0.16 | $-0.11 | $0.19 | $0.20 | $0.14 | $0.06 | $0.20 | $0.06 | $0.03 | $0.06 | $0.01 |
| Low Forecast | - | - | - | - | $0.68 | $0.64 | $0.59 | $0.51 | $0.38 | $0.39 | $0.35 | $0.31 | $0.32 | $0.30 | $0.31 | $0.22 | $0.18 | $-0.08 | $0.15 | $0.16 | $-0.11 | $0.19 | $0.20 | $0.14 | $0.06 | $0.20 | $0.06 | $0.03 | $0.06 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 1.62% | 0.75% | 0.84% | 1.20% | 1.12% | 1.48% | 4.92% | 0.61% | 5.10% | 0.17% | 1.57% | -10.00% |
According to 10 Wall Street analysts, Exelixis's projected average Quarter EPS for Dec 23 is $0.23, with a low estimate of $0.18 and a high estimate of $0.26. This represents a 6808.18% increase compared to EXEL previous annual EPS of - (Sep 23).
Exelixis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics | $0.57 | $12.00 | 2005.26% | Buy |
| KOD | Kodiak Sciences | $3.30 | $31.60 | 857.58% | Buy |
| XFOR | X4 Pharmaceuticals | $0.50 | $3.67 | 634.00% | Buy |
| PDSB | PDS Bio | $3.10 | $9.00 | 190.32% | Buy |
| VKTX | Viking Therapeutics | $64.62 | $100.50 | 55.52% | Buy |
| MDGL | Madrigal Pharmaceuticals | $210.47 | $315.75 | 50.02% | Buy |
| BMRN | BioMarin Pharmaceutical | $69.47 | $103.65 | 49.20% | Buy |
| SRPT | Sarepta Therapeutics | $124.25 | $169.93 | 36.76% | Buy |
| PTCT | PTC Therapeutics | $37.01 | $46.50 | 25.64% | Hold |
| TGTX | TG Therapeutics | $23.94 | $26.40 | 10.28% | Buy |
| HALO | Halozyme Therapeutics | $52.28 | $56.86 | 8.76% | Buy |
| KRYS | Krystal Biotech | $176.82 | $191.00 | 8.02% | Buy |
| EXEL | Exelixis | $29.06 | $28.97 | -0.31% | Buy |
| ALNY | Alnylam Pharmaceuticals | $296.75 | $255.79 | -13.80% | Buy |
EXEL Forecast FAQ
Is Exelixis a good buy?
Yes, according to 16 Wall Street analysts, Exelixis (EXEL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 81.25% of EXEL's total ratings.
What is EXEL's price target?
Exelixis (EXEL) average price target is $28.97 with a range of $18 to $34, implying a -0.31% from its last price of $29.06. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Exelixis stock go up soon?
According to Wall Street analysts' prediction for EXEL stock, the company can go down by -0.31% (from the last price of $29.06 to the average price target of $28.97), up by 17.00% based on the highest stock price target, and down by -38.06% based on the lowest stock price target.
Can Exelixis stock reach $40?
EXEL's average twelve months analyst stock price target of $28.97 does not support the claim that Exelixis can reach $40 in the near future.
What is Exelixis's current price target trend?
9 Wall Street analysts forecast a $28.61 price target for Exelixis (EXEL) this month, down -1.55% from its last price of $29.06. Compared to the last 3 and 12 months, the average price target decreased by -0.34% and decreased by -0.76%, respectively.
What are Exelixis's analysts' financial forecasts?
Exelixis's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.1B (high $2.1B, low $2.1B), average EBITDA is $389.4M (high $389.4M, low $389.4M), average net income is $711.8M (high $711.8M, low $711.8M), average SG&A $586.88M (high $586.88M, low $586.88M), and average EPS is $2.42 (high $2.42, low $2.42). EXEL's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $2.62B (high $2.62B, low $2.62B), average EBITDA is $484.36M (high $484.36M, low $484.36M), average net income is $0 (high $0, low $0), average SG&A $729.99M (high $729.99M, low $729.99M), and average EPS is $0 (high $0, low $0).
Did the EXEL's actual financial results beat the analysts' financial forecasts?
Based on Exelixis's last annual report (Dec 2023), the company's revenue was $1.83B, beating the average analysts forecast of $1.82B by 0.41%. Apple's EBITDA was $196.6M, missing the average prediction of $322.84M by -39.10%. The company's net income was $207.76M, beating the average estimation of $188.79M by 10.05%. Apple's SG&A was $542.7M, beating the average forecast of $462.14M by 17.43%. Lastly, the company's EPS was $0.65, beating the average prediction of $0.641 by 1.48%. In terms of the last quarterly report (Dec 2023), Exelixis's revenue was $479.65M, missing the average analysts' forecast of $480.33M by -0.14%. The company's EBITDA was $88.31M, missing the average prediction of $88.91M by -0.67%. Exelixis's net income was $85.52M, beating the average estimation of $67.02M by 27.61%. The company's SG&A was $131.44M, missing the average forecast of $133.99M by -1.90%. Lastly, the company's EPS was $0, missing the average prediction of $0.228 by -100.00%